Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Safety & Immunogenicity of an Alternative Immunization Schedule of GSK Bio's Pandemic Influenza Vaccine (GSK1119711A)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT00430521
First received: February 1, 2007
Last updated: October 18, 2016
Last verified: October 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: October 2008
  Primary Completion Date: October 2008 (Final data collection date for primary outcome measure)
  Certification or Request for Extension to Delay Results Received: May 20, 2009